{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:06:01Z","timestamp":1767827161415,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:italic>BACKGROUND<\/jats:italic> LY3023414 is a selective, ATP competitive inhibitor of class I PI3K isoforms, mTORC1\/2 and DNA-PK. A Phase 1 dose escalation, 200\u00a0mg twice daily (BID) of LY3023414 was the determined recommended phase 2 dose (RP2D). We report the antitumor activity and safety of LY3023414 monotherapy in patients with advanced mesothelioma.<jats:italic>METHODS<\/jats:italic> Patients enrolled had advanced malignant pleural or peritoneal mesothelioma with measurable disease, ECOG PS 0\u20131, were refractory or ineligible to receive standard therapies. Patients received LY3023414 200\u00a0mg BID. This dose expansion cohort is intended to evaluate preliminary antitumor activity of LY3023414 by overall response rate. Safety, tolerability and pharmacokinetics were assessed. Biomarkers associated with treatment response was an exploratory endpoint. <jats:italic>RESULTS<\/jats:italic> Forty-two patients received LY3023414 for a median duration of 11.2\u00a0weeks (range: 1.1\u201353.0). One patient had a confirmed partial response (PR) (ORR 2.4%). Three patients had an unconfirmed PR. Seventeen patients had stable disease (SD) (DCR 43%). Most common adverse events (AEs) included fatigue (43%), nausea (43%), decreased appetite (38%), vomiting (33%), and diarrhea (29%). AEs were mostly mild or moderate. Grade\u2009\u2265\u20093 AEs were reported for 21% of patients with fatigue as the most frequent event (10%). Alterations of <jats:italic>BAP1<\/jats:italic> were identified in 11\/19 patients as the most common molecular aberration, followed by <jats:italic>SETD2<\/jats:italic> and <jats:italic>NF2<\/jats:italic> alterations. No obvious pattern of genetic changes\/mutations in single genes or pathways was associated with anti-tumor activity. <jats:italic>CONCLUSION<\/jats:italic> LY3023414 monotherapy (200\u00a0mg BID) demonstrated an acceptable and manageable safety profile with limited single-agent activity in patients with advanced mesothelioma. <jats:bold>ClinicalTrials.gov identifier:<\/jats:bold> NCT01655225; <jats:bold>Date of registration:<\/jats:bold> 19 July 2012.<\/jats:p>","DOI":"10.1007\/s10637-021-01086-6","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T04:42:05Z","timestamp":1614832925000},"page":"1081-1088","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Phase 1 cohort expansion study of LY3023414, a dual PI3K\/mTOR inhibitor, in patients with advanced mesothelioma"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5426-0885","authenticated-orcid":false,"given":"Marjorie G.","family":"Zauderer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan W.","family":"Alley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Bendell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Capelletto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd M.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Callies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna M.","family":"Szpurka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhyun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda D.","family":"Willard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Wacheck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna M.","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"issue":"5","key":"1086_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1362","volume":"4","author":"MA Bjornsti","year":"2004","unstructured":"Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4(5):335\u2013348. https:\/\/doi.org\/10.1038\/nrc1362","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1086_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/01.cco.0000198021.99347.b9","volume":"18","author":"Y Samuels","year":"2006","unstructured":"Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18(1):77\u201382","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"1086_CR3","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","volume":"28","author":"KD Courtney","year":"2010","unstructured":"Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28(6):1075\u20131083. https:\/\/doi.org\/10.1200\/JCO.2009.25.3641","journal-title":"J Clin Oncol"},{"key":"1086_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ctrv.2017.07.005","volume":"59","author":"F Janku","year":"2017","unstructured":"Janku F (2017) Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: from laboratory to patients. Cancer Treat Rev 59:93\u2013101. https:\/\/doi.org\/10.1016\/j.ctrv.2017.07.005","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"1086_CR5","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.4155\/fmc.12.56","volume":"4","author":"N Sadeghi","year":"2012","unstructured":"Sadeghi N, Gerber DE (2012) Targeting the PI3K pathway for cancer therapy. Future Med Chem 4(9):1153\u20131169. https:\/\/doi.org\/10.4155\/fmc.12.56","journal-title":"Future Med Chem"},{"issue":"10","key":"1086_CR6","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/bjc.2014.220","volume":"110","author":"S Zhou","year":"2014","unstructured":"Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, Yan Z, Li X, Corson JM, Meng F, Zhou H, Sheng Q, Fletcher JA, Ou WB (2014) Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma. Br J Cancer 110(10):2479\u20132488. https:\/\/doi.org\/10.1038\/bjc.2014.220","journal-title":"Br J Cancer"},{"issue":"10053","key":"1086_CR7","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","volume":"388","author":"Mortality GBD, Causes of Death C","year":"2016","unstructured":"Mortality GBD, Causes of Death C (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015. Lancet 388(10053):1459\u20131544. https:\/\/doi.org\/10.1016\/S0140-6736(16)31012-1","journal-title":"Lancet"},{"key":"1086_CR8","unstructured":"Society AC (2019, January 12) Key statistics about malignant mesothelioma.\u00a0https:\/\/www.cancer.org\/cancer\/malignant-mesothelioma\/about\/key-statistics.html.\u00a0Accessed 10 Dec 2020"},{"issue":"4","key":"1086_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","volume":"16","author":"LM Krug","year":"2015","unstructured":"Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, Ohman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas P (2015) Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 16(4):447\u2013456. https:\/\/doi.org\/10.1016\/S1470-2045(15)70056-2","journal-title":"Lancet Oncol"},{"issue":"9","key":"1086_CR10","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","volume":"18","author":"M Maio","year":"2017","unstructured":"Maio M, Scherpereel A, Calabro L, Aerts J, Cedres Perez S, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL (2017) Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol 18(9):1261\u20131273. https:\/\/doi.org\/10.1016\/S1470-2045(17)30446-1","journal-title":"Lancet Oncol"},{"issue":"17","key":"1086_CR11","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","volume":"25","author":"LL Garland","year":"2007","unstructured":"Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA, Borden EC (2007) Phase II study of erlotinib in patients with malignant pleural mesothelioma: a southwest oncology group study. J Clin Oncol 25(17):2406\u20132413. https:\/\/doi.org\/10.1200\/JCO.2006.09.7634","journal-title":"J Clin Oncol"},{"issue":"3","key":"1086_CR12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejcts.2007.09.045","volume":"33","author":"I Opitz","year":"2008","unstructured":"Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, Moch H, Weder W (2008) PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 33(3):502\u2013506. https:\/\/doi.org\/10.1016\/j.ejcts.2007.09.045","journal-title":"Eur J Cardiothorac Surg"},{"key":"1086_CR13","doi-asserted-by":"publisher","unstructured":"Quetel L, Meiller C, Assi\u00e9 J-B, Blum Y, Imbeaud S, Montagne F, Tranchant R, de Wolf J, Caruso S, Copin M-C, Hofman V, Gibault L, Badoual C, Pintilie E, Hofman P, Monnet I, Scherpereel A, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand M-C, Jean D Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol n\/a (n\/a) https:\/\/doi.org\/10.1002\/1878-0261.12651, 2020","DOI":"10.1002\/1878-0261.12651"},{"issue":"10","key":"1086_CR14","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-15-0996","volume":"15","author":"MC Smith","year":"2016","unstructured":"Smith MC, Mader MM, Cook JA, Iversen P, Ajamie R, Perkins E, Bloem L, Yip YY, Barda DA, Waid PP, Zeckner DJ, Young DA, Sanchez-Felix M, Donoho GP, Wacheck V (2016) Characterization of LY3023414, a novel PI3K\/mTOR dual inhibitor eliciting transient target modulation to impede tumor growth. Mol Cancer Ther 15(10):2344\u20132356. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0996","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"1086_CR15","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1158\/1078-0432.CCR-17-3421","volume":"24","author":"JC Bendell","year":"2018","unstructured":"Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe E, Fink A, Wacheck V, Moore KN (2018) A first-in-human phase 1 study of LY3023414, an oral PI3K\/mTOR dual inhibitor, in patients with advanced Cancer. Clin Cancer Res 24(14):3253\u20133262. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3421","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1086_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15(2):257\u2013260","journal-title":"Ann Oncol"},{"issue":"12","key":"1086_CR17","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","volume":"22","author":"SO Dolly","year":"2016","unstructured":"Dolly SO, Wagner AJ, Bendell JC, Kindler HL, Krug LM, Seiwert TY, Zauderer MG, Lolkema MP, Apt D, Yeh RF, Fredrickson JO, Spoerke JM, Koeppen H, Ware JA, Lauchle JO, Burris HA 3rd, de Bono JS (2016) Phase I study of Apitolisib (GDC-0980), dual Phosphatidylinositol-3-kinase and mammalian target of Rapamycin kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 22(12):2874\u20132884. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2225","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1086_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","volume":"10","author":"SH Ou","year":"2015","unstructured":"Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara DR (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10(2):387\u2013391. https:\/\/doi.org\/10.1097\/JTO.0000000000000360","journal-title":"J Thorac Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01086-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01086-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01086-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:07:13Z","timestamp":1678511233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01086-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1086"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01086-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"assertion":[{"value":"15 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support"}},{"value":"This study was conducted in accordance with the Consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS), International Ethical Guidelines, International Council for Harmonisation Guidelines for Good Clinical Practice (ICH GCP), and applicable local regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent before study entry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have given final approval of this version of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LY3023414 is an orally available PI3K\/mTOR inhibitor, currently in development for the treatment of patients with advanced and\/or metastatic cancer including malignant mesothelioma. This study evaluated safety and preliminary efficacy of LY3023414 monotherapy at the recommended phase 2 dose in patients diagnosed with advanced mesothelioma. Translational research was conducted to understand any association between genomic alteration and clinical activity observed by assessing tumor baseline samples. While limited by the number of tumor samples available, a lower than previously reported incidence of PI3K\/mTOR pathway activating alterations (i.e., PTEN loss) was observed. No obvious association between change in tumor size and biomarkers assessed was identified in patients diagnosed with mesothelioma receiving LY3023414. Pharmacokinetic analysis showed similar properties reported in patients with other cancer type. LY3023414 has an acceptable safety profile with limited single-agent activity in an unselected group of patients with advanced mesothelioma.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of translational relevance"}},{"value":"M. Zauderer reports grants to their institution for research from Eli Lilly and Company, Department of Defense, NCI, Atara Biotherapeutics for research, GSK, Epizyme, Polaris, Sellas Life Sciences, BMS, Millennium\/Takeda, Atara, and Curis; advisory role from Takeda, Aldeyra Therapeutics, Atara Biotherapeutics, GSK, Novocure, Aldeyra, Epizyme; personal fees from Research to Practice, Medical Learning Institute and OncLive, and non-financial support from Roche outside the submitted work.E.W. Alley reports no conflict of interest or financial support.J. Bendell reports research grants from Gilead, Genentech\/Roche, BMS, Five Prime, Eli Lilly and Company, Merck, MedImmune, Celgene, EMD Serono, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Koltan, SynDevRex, Forty Seven, Abbvie, Array, Onyx, Sanofi, Takeda, Eisai, Celldex, Agios, Cytomx, Nektar, ARMO, Boston Biomedical, Ipsen, Merrimack, Tarveda, Tyrogenex, Oncogenex, Marshall Edwards, Pieris, Mersana, Calithera, Blueprint, Evelo, FORMA, Merus, Jacobio, Effector, Novocare, Arrys, Tracon, Sierra, Innate, Arch Oncology, Prelude Therapeutics, Unum Therapeutics, Vyriad, Harpoon, ADC, Amgen, Pfizer, Millennium, Imclome, Acerta Pharma, Rgenix, Bellicum, Gossamer Bio, Arcus Bio, Seattle Genetics, Tepest Tx, Shattuck Labs, Synthorx, Inc., Revolution Medicines, Inc., Bicycle Therapeutics, Zymeworks, Relay Therapeutics, Atlas Medx, Scholar Rock and NGM Biopharma, other payment to institution for consulting services from BMS, Five Prime, Eli Lilly and Company, Merck, Medimmune, Celgene, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Array, Sanofi, Agios, ARMO, Ipsen, Merrimack, Oncogenex, Evelo, FORMA, Innate, Arch Oncology, Prelude Therapeutics, Amgen, Pfizer, Seattle Genetics, Bicycle Therapeutics, Relay Therapeutis, Phoenix Bio, Cyteir, Molecular Partners, Torque, Tizona, Janssen, Tolero, TD2, Moderna Therapeutics, Tanabe Research Laboratories, Beigene, Continuum Clinical, Evelo, Piper Biotech, Samsung Bioepios, outside the submitted work.E. Capelleto reports other payment for consulting services from Boehringer Ingelheim and Astrazeneca; other payments for an advisory role at MSD, outside the submitted work.T. Bauer reports grants from Eli Lilly and Company, during the conduct of the study; grants from Daiichi Sankyo, grants from Medpacto, grants from Incyte, grants from Mirati Therapeutics, grants from MedImmune, grants from Abbvie, grants from AstraZeneca, grants from MabVax, grants from Stemline Therapeutics, grants from Merck, grants from Lilly, grants from GlaxoSmithKline, grants from Novartis, grants from Genentech, grants from Deciphera, grants from Merrimack, grants from Immunogen, grants from Millennium, grants from Phosplatin Therapeutics, grants from Calithera Biosciences, grants from Kolltan Pharmaceuticals, grants from Principa Biopharma, grants from Peleton, grants from Immunocore, grants from Roche, grants from Aileron Therapeutics, grants from Bristol-Myers Squibb, grants from Amgen, grants from Onyx, grants from Sanofi, grants from Boehringer-Ingelheim, grants from Astellas Pharma, grants from Five Prime Therapeutics, grants from Jacobio, grants from Top Alliance BioScience, grants from Janssen, grants from Clovis Oncology, grants from Takeda, grants from Karyopharm Therapeutics, grants from Foundation Medicine, grants from ARMO Biosciences, grants and other from Leap Therapeutics, grants, non-financial support and other from Ignyta, grants, non-financial support and other from Moderna Therapeutics, grants, personal fees and other from Pfizer, grants, personal fees and non-financial support from Loxo, grants, personal fees and non-financial support from Bayer, personal fees and non-financial support from Guardant Health, personal fees from Exelesis, outside the submitted work.S. Callies, A.M. Szpurka, S. Kang, M.D. Willard are employees of Eli Lilly and Company; M.D. Willard report other payments as a stockholder for Eli Lilly and Company.V. Wacheck reports payment as a former employee and shareholder for Eli Lilly and Company during the conduct of this study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}